RxDoctor Payments DataLook up a doctor →

Kayla Stanage, APRN

Family · Hot Springs, ARNPI 1982133161

Payments from drug & device makers

$10,063in general payments, 2019–2025

Across 654 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$855
  • Amgen$654
  • Lilly USA, LLC$486
  • Otsuka America Pharmaceutical, Inc.$479
  • Axsome Therapeutics, Inc.$450
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,97899%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,063 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$25,064
Medicare patients
148
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$107,640
FarxigaDapagliflozin Propanediol51$74,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$38,084
JanuviaSitagliptin Phosphate29$30,596
EliquisApixaban29$28,334
OzempicSemaglutide17$22,837
JardianceEmpagliflozin18$19,692
RexultiBrexpiprazole11$18,472
TrulicityDulaglutide15$15,750
XareltoRivaroxaban16$15,436
GemtesaVibegron13$9,039
Tresiba Flextouch U-100Insulin Degludec16$7,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,876
Soliqua 100-33Insulin Glargine/Lixisenatide15$6,044
Breo ElliptaFluticasone/Vilanterol13$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$486$123,389111 claims
AstraZenecaFarxiga, Breztri Aerosphere$855$81,46762 claims
GSKTrelegy Ellipta, Breo Ellipta$385$42,84651 claims
MerckJanuvia$91$30,59629 claims
PfizerEliquis$268$28,33429 claims
Novo NordiskOzempic$194$22,83717 claims
Boehringer IngelheimJardiance$129$19,69218 claims
Otsuka America Pharmaceutical, Inc.Rexulti$479$18,47211 claims
Johnson & JohnsonXarelto$326$15,43616 claims
Sumitomo Pharma America, Inc.Gemtesa$204$9,03913 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$19$6,04415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →